Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus PALIPERIDONE PALMITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus PALIPERIDONE PALMITATE.
LYBALVI vs PALIPERIDONE PALMITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Paliperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also blocks alpha-2 adrenergic and H1 histaminergic receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
Paliperidone palmitate is administered intramuscularly. Initial dose: 150 mg eq. on day 1 and 100 mg eq. on day 8, both in the deltoid muscle. Maintenance dose: 75 mg eq. monthly (range 25–150 mg eq.) administered in the deltoid or gluteal muscle.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life: 25-49 days (mean ~30 days) for IM injection; allows monthly dosing
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Renal: 80% as unchanged drug and metabolites; fecal: 11%
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic